American Society of Hematology

Schedule and Program

Please note: the following information is preliminary and subject to change.

Thursday, July 12, 2018

8:00 a.m. – 7:00 p.m.Registration
8:00 a.m. – 8:45 a.m.Breakfast and Exhibits
8:45 a.m. – 9:05 a.m.Welcome, Introduction, and Announcements

Catherine M. Bollard, MD, Children's National Medical Center
Program Co-Chair

Rodrigo T. Calado, MD, PhD, University of São Paulo
Program Co-Chair

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center
Program Co-Chair

Jeffrey S. Miller, MD, University of Minnesota
Program Co-Chair

Sophie Paczesny, MD, Indiana University School of Medicine
ASH Task Force on Immunotherapies Co-Chair

Steven Pavletic, MD, National Cancer Institute, National Institutes of Health
ASH Task Force on Immunotherapies Co-Chair

9:05 a.m. – 11:05 a.m.Cellular Therapies and Their Role in the Treatment of Malignant and Non-Malignant Hematologic Disease

Chair:

Jeffrey S. Miller, MD, University of Minnesota

Speakers:

Stanley R. Riddell, MD, Fred Hutchinson Cancer Research Center
CAR-T Cell Therapy

Helen E. Heslop, MD, DSc, Baylor College of Medicine
Antigen Specific T-Cell Therapy

Jeffrey S. Miller, MD, University of Minnesota
Natural Killer Cells to Treat or Prevent Cancer Relapse

Bruce R. Blazar, MD, University of Minnesota
Immune Regulatory Cell Therapies for Graft Versus Host Disease
11:05 a.m. – 11:35 a.m.Panel Discussion

Moderator:

Jeffrey S. Miller, MD, University of Minnesota
11:35 a.m. – 12:35 p.m.Lunch
12:35 p.m. – 2:35 p.m.Engineered and Non-Engineered T Cells as Tools for Immunotherapy: Beyond CAR T Cells

Chair:

Catherine M. Bollard, MD, Children's National Medical Center

Speakers:

Stephen M. Ansell, MD, PhD, Mayo Clinic
Checkpoint Inhibitors

Stephen Gottschalk, MD, Baylor College of Medicine
BiTEs, DARTs, and Other Bispecifics

Ronald Levy, MD, Stanford University
Combining Intratumoral Injections of TLR Agonists With Checkpoint Antibodies

Danielle Townsley, MD, National Heart, Lung, and Blood Institute, National Institutes of Health
Augmenting the Efficacy of Immunotherapy for Aplastic Anemia
2:35 p.m. – 3:05 p.m.Panel Discussion

Moderator:

Jeffrey S. Miller, MD, University of Minnesota
3:05 p.m. – 3:20 p.m. Networking Coffee Break
3:20 p.m. – 4:20 p.m.Company Presentations
4:20 p.m. – 6:20 p.m.Effective Clinical Trial Design in the Field of Immunotherapy

Chair:

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Speakers:

James Kochenderfer, MD, National Cancer Institute, National Institutes of Health
CAR T Cells: The Balance of Efficacy and Toxicity

Marcelo C. Pasquini, MD, Medical College of Wisconsin
Developing Cell Therapies in a Cooperative Group Setting

Alexander M. Lesokhin, MD, Memorial Sloan Kettering Cancer Center
Combining Immunotherapies: Experience So Far

Yogen Saunthararajah, MD, Cleveland Clinic
Immunotherapies for Myelodysplastic Syndromes: To Modulate or Augment?
6:20 p.m. – 6:50 p.m.Panel Discussion

Moderator:

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center
7:00 p.m. – 8:30 p.m.Welcome and Networking Reception
back to top

Friday, July 13, 2018

8:00 a.m. – 4:00 p.m.Registration
8:00 a.m. – 9:00 a.m.Breakfast and Exhibits
9:00 a.m. – 9:20 a.m.Opening Remarks

Catherine M. Bollard, MD, Children's National Medical Center
Program Co-Chair

Rodrigo T. Calado, MD, PhD, University of São Paulo
Program Co-Chair

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center
Program Co-Chair

Jeffrey S. Miller, MD, University of Minnesota
Program Co-Chair

9:20 a.m. – 11:50 a.m.Breakout Sessions

Breakout I: Preparing the Garage: How to Prepare for the Commercialization of CAR T Cells in Your Institution

Chair:

Catherine M. Bollard, MD, Children's National Medical Center

Breakout II: Toxicity Management: Can We Make This Easier?

Chair:

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Breakout III: The Challenge Beyond CAR T: What Does the Future Offer for Commercial Immunotherapies and Combinations?

Chair:

Jeffrey S. Miller, MD, University of Minnesota

Breakout IV: Immunotherapy: Going Beyond Cancer

Chair:

Rodrigo T. Calado, MD, PhD, University of São Paulo
11:50 a.m. – 1:00 p.m.Lunch
1:00 p.m. – 1:50 p.m.Company Presentations
1:50 p.m. – 2:50 p.m.Reports From Breakout Sessions
2:50 p.m. – 3:05 p.m.Panel Discussion

Moderators:

Catherine M. Bollard, MD, Children's National Medical Center

Rodrigo T. Calado, MD, PhD, University of São Paulo

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Jeffrey S. Miller, MD, University of Minnesota
3:05 p.m. – 3:50 p.m.Closing Keynote Address

Steven A. Rosenberg, MD, PhD, National Cancer Institute, National Institutes of Health
Cellular Immunotherapy From Tumor-Infiltrating Lymphocytes to CAR T Cells and Beyond
3:50 p.m. – 4:10 p.m.Closing Remarks

Catherine M. Bollard, MD, Children's National Medical Center
Program Co-Chair

Rodrigo T. Calado, MD, PhD, University of São Paulo
Program Co-Chair

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center
Program Co-Chair

Jeffrey S. Miller, MD, University of Minnesota
Program Co-Chair

back to top